Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | NIN |
| Gene Name: | NIN |
| Protein Full Name: | Ninein |
| Alias: | Glycogen synthase kinase 3 beta-interacting; Glycogen synthase kinase 3 beta-interacting protein; GSK3B interacting protein; GSK3B-interacting; HNinein; Ninein (GSK3B interacting protein) |
| Mass (Da): | 243290 |
| Number AA: | 2090 |
| UniProt ID: | Q8N4C6 |
| Locus ID: | 51199 |
| COSMIC ID: | NIN |
| Gene location on chromosome: | 14q22.1 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19981 |
| Percent of cancer specimens with mutations: | 1.53 |
| Deregulated in translocations: | Atypical Chronic Myeloid Leukemia (aCML), fusion partner is PDGFRB. |
| Normal role description: | NIN is a centrosome-associated protein required for positioning and anchoring of microtubule during mitosis. NIN is found to interact with GSK3beta and may be regulated through phosphorylation. Mutations of NIN have been detected in cancer but their functional effects have not been characterized. The NIN gene locus can participate in a translocation event to create a fusion protein with the platelet-derived growth factor receptor beta (PDGFRB) subunit which has been implicated in Atypical Chronic Myeloid Leukemia. |
| Commentary on involvement of protein in cancer: | Less than 3% mutation in CNS and kidney. |